Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | MMP1 | P03956 | 1/20 | 0.31 |
| ▸ | MMP8 | P22894 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23896833 | 0.83 | — | — | |
| SCHEMBL6960468 | 0.81 | KDM1A (0.32) | CYP2C19 | |
| SCHEMBL14773217 | 0.77 | — | — | |
| SCHEMBL11477580 | 0.77 | — | — | |
| SCHEMBL25761105 | 0.77 | — | — | |
| SCHEMBL13670700 | 0.77 | — | — | |
| SCHEMBL9353816 | 0.75 | — | — | |
| SCHEMBL16259082 | 0.75 | CYP2D6 (0.38) | CYP2D6CYP2C19MMP1MMP8 | |
| SCHEMBL24961919 | 0.75 | — | — | |
| SCHEMBL9353813 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220017566-A1 | TERPINOID DERIVATIVES AND USES THEREOF | FRONTHERA U.S. PHARMACEUTICALS LLC | 2022-01-20 | — | — | US | disclosed |
| WO-2021202720-A1 | USE OF TRITERPENOID NRF2 INHIBITORS | FRONTHERA U.S. PHARMACEUTICALS LLC (US) | 2021-10-07 | — | — | WO | disclosed |
| WO-2020068689-A1 | TERPINOID DERIVATIVES AND USES THEREOF | FRONTHERA U.S. PHARMACEUTICALS LLC (US) | 2020-04-02 | — | — | WO | disclosed |
| US-20110098471-A1 | OXAZOLIDINONE DERIVATIVE HAVING FUSED RING | RESEARCH FOUNDATION ITSUU LABORATORY (JP) | 2011-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098471-A1 | OXAZOLIDINONE DERIVATIVE HAVING FUSED RING | OXER1, ALOX12, CYP1A1 | CYP2D6 49/4885CYP2C19 266/4885MMP1 2108/4885 |
| US-20220017566-A1 | TERPINOID DERIVATIVES AND USES THEREOF | KEAP1, PTGES, GSTK1 | CYP2D6 2825/4885CYP2C19 2773/4885MMP1 3283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.